Related Experiment Video

Updated: Feb 14, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

429

Synergistic Gene Immunotherapy for Lung Cancer via Targeted Nanomedicine Restoring Genetic Tumor Suppression and

Weiyu Chen1,2, Xinjie Zheng1, Yuan Wu1,3

  • 1Department of Respiratory and Critical Care Medicine, Center for Oncology Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.

ACS Nano
|February 12, 2026
PubMed

Insights

A novel nanomedicine targets non-small cell lung cancer (NSCLC) by delivering a tumor suppressor gene and immune activator. This gene-immunotherapy shows specific NSCLC suppression and potent antitumor effects in vivo.

Area of Science:

  • Oncology
  • Nanomedicine
  • Gene Therapy
  • Immunotherapy

Background:

  • Non-small cell lung cancer (NSCLC) has high mortality and complex pathogenesis.
  • Current treatments like chemotherapy and immunotherapy show limitations for comprehensive NSCLC inhibition.
  • Novel therapeutic strategies are needed for effective NSCLC treatment.

Purpose of the Study:

  • To develop a novel gene-immunotherapeutic nanomedicine for NSCLC.
  • To investigate the targeted delivery and therapeutic efficacy of the nanomedicine.
  • To evaluate the activation of the cGAS/STING pathway and in vivo antitumor effects.

Main Methods:

  • Development of pTMEM163/cGAMP@cRGD-BSA/LDHs (TGR-BLDHs) nanomedicine.
  • Utilizing cyclic Arg-Gly-Asp (cRGD)-modified bovine serum albumin/layered double hydroxide (BSA-LDH) nanoparticles.
  • Targeted delivery of TMEM163 tumor suppressor gene and cGAS/STING agonist (cGAMP).

Main Results:

  • TGR-BLDHs demonstrated highly specific NSCLC tumor suppression through targeted gene therapy.
  • The nanomedicine activated the cGAS/STING pathway in antigen-presenting and cancer cells.
  • TGR-BLDHs successfully inhibited tumor progression in vivo, showing potent antitumor effects.

Conclusions:

  • TGR-BLDHs represent a promising gene-immunotherapeutic strategy for NSCLC.
  • The nanomedicine offers desirable tumor specificity and biocompatibility.
  • This approach provides a new avenue for effective NSCLC treatment.
Keywords:
STING agonistgene immunotherapylayered double hydroxidestumor suppressor genetumor-targeted delivery

More Related Videos

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines07:59

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines

Published on: March 4, 2017

9.5K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.6K
Restorative Care01:19

Restorative Care

Restorative care is provided once a patient has been discharged from a healthcare facility and requires additional services. The additional services include home care, rehabilitation programs, and extended care. Restorative care centers help the patient regain their previous level of functioning or acquire a new level of functioning due to the incapacitating effects of a disease or a disability. It aims to assist patients in enhancing their quality of life by encouraging independence,...
2.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Genetics of Speciation02:16

Genetics of Speciation

Speciation is the evolutionary process resulting in the formation of new, distinct species—groups of reproductively isolated populations.
21.9K